Phase 3 PEACE-3 Study of Enzalutamide + Ra-223: Efficacy Data

Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor (ARPI)–naive metastatic castration-resistant prostate cancer (mCRPC), focusing on the impact of the combination on radiographic progression-free survival (rPFS) and overall survival (OS), and how these results inform clinical decision-making regarding treatment strategies for mCRPC.

EP: 1.Introduction & Case 1 Presentation: mHSPC

EP: 2.Newly diagnosed Diagnosed mHSPC: Goals of Therapy

EP: 3.Newly Diagnosed mHSPC: First-Line Treatment Options

EP: 4.Newly Diagnosed mHSPC: Androgen Receptor Pathway Inhibitor Selection

EP: 5.Case 1 Presentation (cont): mHSPC

EP: 6.Phase 3 ARANOTE Study of ADT + Darolutamide

EP: 7.Phase 3 ARANOTE Study of ADT + Darolutamide: Safety

EP: 8.mHSPC: Applying Data Toward Treatment Decision-Making

EP: 9.Adding Chemotherapy for a Patient Receiving ADT + an ARPI

EP: 10.Case 2 Presentation: mCRPC

EP: 11.Guideline-Directed Treatment Options: mCRPC

EP: 12.Phase 3 PEACE-3 Study of Enzalutamide + Ra-223: Design

Now Viewing

EP: 13.Phase 3 PEACE-3 Study of Enzalutamide + Ra-223: Efficacy Data

EP: 14.Phase 3 PEACE-3 Study of Enzalutamide + Ra-223: Safety

Video content above is prompted by the following:

What were the key efficacy findings from the PEACE-3 study? How do you interpret and think about the results (eg, rPFS, OS)?

Recent Videos